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Objectives This study presents long-term clinical follow-up, including binary restenosis rate and
major adverse cardiovascular events, of the PACCOCATH-ISR (Treatment of In-Stent Restenosis by
Paclitaxel Coated PTCA Balloons) I and II trial.
Background The PACCOCATH-ISR trial was a ﬁrst-in-human study with a drug-coated balloon cathe-
ter and the ﬁrst study for the treatment of coronary ISR with a drug-coated balloon. So, far no long-
term follow-up data have been presented.
Methods This study enrolled 108 patients in a randomized, double-blinded multicenter trial on the
efﬁcacy and safety of a paclitaxel-coated balloon (3 g/mm2 balloon surface; PACCOCATH [Bayer
AG, Leverkusen, Germany]) compared with an uncoated balloon. The main inclusion criteria were a
diameter stenosis of 70% and 30-mm length with a vessel diameter of 2.5 to 3.5 mm. The pri-
mary endpoint was angiographic late lumen loss in-segment after 6 months. Combined antiplatelet
therapy was continued only for 1 month followed by treatment with aspirin alone.
Results During a follow-up of 5.4  1.2 years, the clinical event rate was signiﬁcantly reduced in
patients treated with the drug-coated balloon (major adverse cardiovascular events: 59.3% vs. 27.8%,
p  0.009), which was mainly driven by the reduction of target lesion revascularization from 38.9%
to 9.3% (p  0.004).
Conclusions Treatment of coronary ISR with paclitaxel-coated balloon catheters is safe and persis-
tently reduces repeat revascularization during long-term follow-up. The initial results were sustained
over the 5-year period. (Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons
[PACCOCATH ISR I]; NCT00106587. Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Bal-
loons [PACCOCATH ISR II]; NCT00409981) (J Am Coll Cardiol Intv 2012;5:323–30) © 2012 by the
American College of Cardiology Foundation
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324Coronary angioplasty was pioneered by Andreas Grüntzig in
1977 (1). A remarkable improvement of angioplasty has been
achieved with the introduction of stents overcoming elastic
recoil and dissections (2). However, restenosis due to neointi-
mal proliferation was not affected. Local intravascular drug
delivery by drug-eluting stents (DES) seemed to overcome the
problem of restenosis (3). However, stents cannot be implanted
t all sites where neointimal proliferation limits the long-term
enefit of angioplasty. Furthermore, the need for long-term
ual antiplatelet therapy due to delayed and incomplete endo-
helialization limits the use of this kind of therapy. The
oncept of intramural drug delivery independent from a stent
latform became embodied in a drug-coated balloon (DCB)
oncept (4,5). By coating paclitaxel onto the surface of a conven-
ional angioplasty balloon used to dilate the stenotic artery an
xclusively local effect could theoretically be achieved, with the
rug transferred to the dilated segment as the balloon is inflated.
n this way, an effective local drug concentration was achieved with
ery low systemic exposure (4).
Paclitaxel is characterized by a high lipophilicity and tight
binding to various cell constituents, resulting in effective
local retention at the site of de-
livery (6–8). The addition of a
contrast agent resulted in a sol-
ubility of paclitaxel far beyond the
concentrations applied in previous
investigations (9). In vitro and in
vivo experiments identified a spe-
cific coating with paclitaxel in
combination with the hydrophilic
X-ray contrast medium iopromide
(Ultravist, Bayer HealthCare Phar-
maceuticals, Wayne, New Jersey) to
be effective for restenosis prevention (PACCOCATH) (Bayer
AG, Leverkusen, Germany) (4,10).
The first accepted coronary indication for DCB was
the treatment of in-stent restenosis (ISR). Based on the
results of the PACCOCATH ISR (Treatment of In-
Stent Restenosis by Paclitaxel Coated PTCA Balloons)
(5,11) and PEPCAD (Paclitaxel-Eluting PTCA-Balloon
Catheter in Coronary Artery Disease) II (12) trials, the
European Society of Cardiology/European Association
for Cardio-Thoracic Surgery guidelines for coronary
revascularization gave a class IIa recommendation for this
treatment modality. The first-in-human PACCOCATH
ISR trial compared the efficacy and tolerance of the
PACCOCATH prototype DCB (Bayer AG) with con-
ventional uncoated catheters for the treatment of coro-
nary ISR (5). The longest available clinical follow-up was
2 years (11). In this paper, we present the clinical long-term
follow-up data of these first-in-human patients enrolled in the
PACCOCATH ISR trial after treatment of coronary ISR
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DCB  drug-coated
balloon(s)
DES  drug-eluting stent(s)
ISR  in-stent restenosis
TIMI  Thrombolysis In
Myocardial Infarctionwith a paclitaxel-coated balloon or an uncoated balloon.Methods
Study design. A total of 108 patients were enrolled in 2
eparately randomized study blocks (PACCOCATH ISR I
5) and ISR II (11)) investigating the efficacy and safety of
paclitaxel-coated balloon (3 g/mm2 balloon surface;
PACCOCATH) (Bayer AG). The study was conducted at
Table 1. Baseline Clinical and Angiographic Data, Procedural Data
(Intention-to-Treat Analysis)
Uncoated
Balloon
(n  54)
Drug-Coated
Balloon
(n  54) p Value
Age, yrs 66.3 9.8 65.4 10.3 0.805
Male 31 (57) 42 (78) 0.125
Diabetes mellitus 17 (31) 12 (17) 0.313
Insulin-dependent 6 (11) 3 (6)
Hyperlipidemia 39 (72) 42 (78) 0.485
Smoking 26 (48) 23 (43) 0.772
Hypertension 44 (82) 44 (82) 0.866
Unstable angina 22 (41) 20 (37) 1.000
No. of diseased vessels 0.495
1 13 (24) 9 (17)
2 19 (35) 24 (44)
3 22 (41) 21 (39)
Treated vessel 0.611
RCA 17 (32) 18 (33)
LCX 12 (22) 13 (24)
LAD 25 (46) 23 (43)
Patterns of ISR* 0.377
IA 0 0
IB 3 (6) 0
IC 8 (15) 11 (20)
ID 2 (4) 0
II 25 (46) 26 (48)
III 14 (26) 11 (20)
IV 2 (4) 6 (11)
Study balloon
Diameter, mm 3.0 0.3 3.0 0.3 1.000
Length, mm 24.3 5.0 24.1 4.9 0.592
Mean pressure, atm 12.7 2.7 12.5 2.6 0.819
Balloon inﬂation time, s 68.9 37.7 77.2 42.2 0.063
Restenotic stent type 1.000
BMS 52 (96) 52 (96)
DES 2 (4) 2 (4)
Restenotic stent
Diameter, mm 3.0 0.3 3.0 0.3 0.910
Length, mm 18.4 4.9 20.8 7.3 0.058
Additional stents 2 (4) 3 (6) 1.000
GP IIb/IIIa antagonists 7 (13) 5 (9) 1.000
Values are mean  SD or n (%). *Patterns of in-stent restenosis according to the Mehran
classification (13). The p values were adjusted according to the Fisher method of combining
independent tests.
BMS  bare-metal stent(s); DES  drug-eluting stent(s); GP  glycoprotein; ISR  in-stent
restenosis; LAD left anterior descending coronary artery; LCX left circumflex coronary artery;RC right coronary artery.
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3255 departments of cardiology at the medical schools of the
universities of Berlin, Freiburg, Homburg/Saar, and Mann-
heim/Heidelberg in Germany. Financial support was provided
by Bavaria Medizintechnik GmbH, Oberpfaffenhoven, Ger-
many, the manufacturer of the balloon catheters used in this
study. The sponsor had no role in the design or conduct of the
study, in the analysis of the results, in the decision to publish,
or in the drafting of the manuscript. The long-term
follow-up data were obtained by the authors without external
financial support. The authors vouch for the accuracy and
completeness of the data presented.
The study was performed according to the Declaration of
Helsinki and World Health Organization guidelines. Fur-
thermore, the requirements of sections 20 to 22 of the
German Medical Device Law as well as the European
standard EN 540 were followed. All patients gave written
informed consent. The study was approved by the local
ethics committees.
Details of the methods and results up to 2 years have been
previously published (5,11). Patients at least 18 years of age
with clinical evidence of stable or unstable angina or a
positive functional study and a single restenotic lesion in a
stented coronary artery with bare-metal stents (BMS) or
DES, were considered for enrollment. Major clinical exclu-
sion criteria were: acute myocardial infarction within the
past 72 h; chronic renal insufficiency with serum creatinine
levels 2.0 mg/dl; known hypersensitivity or contraindica-
ions to aspirin, heparin, clopidogrel, abciximab, or pacli-
axel; and sensitivity to contrast media not amenable to
Table 2. Angiographic Findings at Treatment and 6-M
U
(
Angiographic measurements at treatment
Left ventricular function, % 60
Lesion length, mm 18
Reference diameter, mm 2.
Minimal lumen diameter initial, mm 0.
Minimal lumen diameter after angioplasty, mm 2.
Findings at follow-up angiography (6 months)
Follow-up angiography
Left ventricular function, % 61
Minimal lumen diameter at follow-up, mm
In-stent 1.
In-segment 1.
Late lumen loss, mm
In-stent 0.
In-segment 0.
Binary restenosis rate
In-stent
In-segment
Values are mean SD or n (%). The p values were adjusted accordingCI confidence interval.pre-medication. Cardiac catheterization pre-medication and
medication during the intervention was carried out according
to hospital practice. Glycoprotein IIb/IIIa antagonists were
administered at operator’s discretion.
After assessment for angiographic exclusion criteria, each
suitable patient was randomly assigned to undergo balloon
angioplasty of the target lesion with either a paclitaxel-
coated or an uncoated balloon catheter. Standard angio-
plasty catheters (Orbus X, Bavaria Medizin Technologie
GmbH, Oberpfaffenhofen, Germany) were supplied either
uncoated or coated with a paclitaxel dose of 3 g/mm2 on
he balloon surface.
Pre-dilation of the target lesion was usually performed
efore the study intervention, using a nonstudy balloon
atheter with a diameter 0.5 mm smaller than the study
alloon. Study balloon inflation was performed in the same
ashion as the inflation of a conventional balloon catheter.
ecommended balloon inflation time was 60 s. Immediately
ollowing the procedure, heparin was discontinued. Vascular
heaths were removed according to usual hospital practice.
Quantitative coronary angiography. Angiography was per-
formed before and after all interventions and at angio-
graphic follow-up using identical projections and analyses.
Quantitative analysis of the coronary angiographic images
was performed by an independent, blinded core laboratory.
The CAAS II Research System (Pie Medical Imaging,
Maastricht, the Netherlands) was used for automated con-
tour detection and quantification. Measurements were ob-
tained in the inner stenotic area, in the stented area with
Follow-Up (Intention-to-Treat Analysis)
d
n
)
Drug-Coated
Balloon
(n  54)
Difference
(95% CI) p Value
3.9 60.8 14.5 –0.49 (–6.2 to 5.2) 0.862
.3 18.3 9.7 0.28 (–3.41 to 3.97) 0.845
.37 2.94 0.35 –0.05 (–0.25 to 0.14) 0.731
.35 0.63 0.29 0.07 (–0.06 to 0.21) 0.015
.44 2.43 0.47 –0.09 (–0.27 to 0.09) 0.955
) 48 (87) 0.944
4.1 60.1 14.7 1.0 (–5.2 to 7.2) 0.816
.81 2.30 0.62 –0.77 (–1.06 to 0.47) 0.003
.79 2.23 0.57 –0.72 (–1.01 to 0.44) 0.004
.79 0.14 0.46 0.67 (0.41 to 0.93) 0.001
.79 0.11 0.44 0.69 (0.44 to 0.96) 0.001
) 3 (6) 0.39 (0.24 to 0.54] 0.001
) 3 (6) 0.41 (0.26 to 0.56) 0.001
isher method of combining independent tests.onth
ncoate
Balloo
n  54
.3 1
.6 8
94 0
70 0
34 0
49 (91
.1 1
53 0
50 0
81 0
80 0
24 (49
25 (51
to the F
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326measurement shoulder to shoulder (in-stent), and in the
total stented area plus 5 mm proximally and distally (in-
segment). Restenosis was defined as 50% diameter steno-
sis at angiographic follow-up. Patterns of ISR were defined
according to the Mehran classification (13).
Follow-up and endpoints. Aspirin (100 mg) and clopidogrel
(75 mg) were continued orally for 1 month, followed by
treatment with aspirin alone. Patients underwent follow-up
angiography after 6 months (up to 9 months) and were
followed up for 6 months, 12 months, 2 years, and 5 years
(maximum 6.4 years) by clinical observation. All endpoints
and adverse events were evaluated in consensus by the
Figure 1. Study Flow ChartsDisposition of patients (n*  number of patients for whom information about theirinvestigators. The investigators and the core laboratory
remained blinded until the database was closed.
Long-term clinical follow-up after 5 years was defined in
the study protocol. Patient’s medical history was evaluated
by: telephone interviews; a questionnaire on their actual
health status and clinical events in the period between 2 and
5 years after randomization; patient’s records reviews; and
contacting patients’ treating physicians.
Angiographic late lumen loss (difference between the
post-procedural and 6-month follow-up in-segment mini-
mal lumen diameter; evaluated by quantitative coronary
angiography) was the primary endpoint. Secondary end-health condition was available). FUP  follow-up; ITT  intention-to-treat.
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327points included binary angiographic restenosis rate (diame-
ter stenosis of at least 50% assessed by quantitative coronary
angiography at 6-month follow-up) and combined clinical
endpoints with a follow-up up to 5 years, including acute and
subacute stent thrombosis, target lesion revascularization, myo-
cardial infarction, cerebral stroke, and death. The results of the
primary angiographic endpoint have been published before
(5,11).
Acute stent thrombosis was defined as the occurrence of
ew severely reduced flow (TIMI [Thrombolysis In Myo-
ardial Infarction] flow grade 0 or 1) within the target vessel
uring the intervention that persisted and required rescue by
nonassigned treatment strategy or resulted in myocardial
nfarction or death. Subacute stent thrombosis was defined
s vessel closure occurring during follow-up. Target lesion
evascularization was defined as percutaneous reintervention
r coronary artery bypass graft surgery involving the target
esion. The decision to perform a reintervention procedure
as based on symptoms, anatomic findings at follow-up
ngiography, or both.
Myocardial infarction was assumed if 2 of the following 5
riteria applied: 1) chest pain lasting longer than 30 min;
Table 3. Clinical Follow-Up (Intention-to-Treat Analys
Uncoated
Balloon
(n  54)
12-month clinical follow-up (total event
rate from baseline to 12 months)
Target lesion revascularization 20 (37)
Myocardial infarction 5 (9)
Death 3 (6)
Stroke 2 (4)
Stent thrombosis 0
MACE 24 (44)
2-yr clinical follow-up (total event rate
from baseline to 24 months)
Target lesion revascularization 20 (37)
Myocardial infarction 5 (9)
Death 3 (6)
Stroke 3 (6)
Stent thrombosis 0
MACE 25 (46)
5-yr clinical follow-up (total event rate
from baseline to 5.4 1.2 yrs)
Follow-up, yrs 5.2 1.5
Target lesion revascularization 21 (38.9)
Myocardial infarction 8 (14.8)
Death 8 (14.8)
Stroke 5 (9.3)
Stent thrombosis 0
MACE 32 (59.3)
Values are n (%) or mean SD. The p values were adjusted according
lesion revascularization, myocardial infarction, stroke, and death.CI confidence interval; MACEmajor adverse cardiac events; OR odd) significant electrocardiographic changes typical of acute
yocardial infarction (0.1-mV ST-segment elevation in at
east 2 adjacent electrocardiogram leads or new occurrence
f a complete left bundle branch block); 3) significant
ncrease (3 above normal) of creatinine kinase or its
yocardial band isoform; 4) new significant Q waves; or
) chest pain leading to angiography up to 6 h after the
nset of symptoms and showing a totally occluded vessel
ompared with the previous angiogram. Deaths were doc-
mented and confirmed from hospital records or by con-
acting the patient’s relatives or the treating physician.
Statistical analysis. Analysis of the data for all endpoints
was performed according to intention-to-treat. Continuous
data are expressed as mean  SD. Categorical variables
were compared using the 2-sided chi-square test, and
continuous variables were compared using 2-sided Student t
test. Confidence intervals for the difference of proportions
were calculated using normal approximation of the binomi-
nal distribution without correction for continuity. Event-
free survival was compared by Kaplan-Meier analysis using
a log-rank test (Mantel-Cox) (SPSS, version 19.0, SPSS
Inc., Chicago, Illinois). The p values were adjusted accord-
Drug-Coated
Balloon
(n  54)
Risk Estimate
OR (95% CI) p Value
2 (4) 0.07 (0.01–0.30) 0.001
1 (2) 0.19 (0.02–1.64) 0.577
2 (4) 0.65 (0.11–4.08) 0.912
2 (4) 1.00 (0.14–7.37) 1.000
0 1.000
5 (9) 0.13 (0.04–0.37) 0.001
3 (6) 0.10 (0.03–0.36) 0.001
1 (2) 0.19 (0.02–1.64) 0.577
2 (4) 0.65 (0.11–4.08) 0.912
2 (4) 0.65 (0.11–4.08) 0.840
0 1.000
6 (11) 0.15 (0.05–0.40) 0.001
5.6 0.9 0.222
5 (9.3) 0.16 (0.055–0.468) 0.004
5 (9.3) 0.59 (0.179–1.924) 0.510
5 (9.3) 0.59 (0.179–1.924) 0.938
5 (9.3) 1.00 (0.272–3.674) 1.000
0 1.000
15 (27.8) 0.26 (0.118–0.592) 0.009
isher method of combining independent tests. MACE includes targetis)
to the Fs ratio.
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328ing to the Fisher method of combining independent tests. A
2-sided p value of 0.05 was considered significant.
Results
A total of 108 patients were enrolled and were randomly
assigned to the uncoated-balloon group (n  54) and to the
coated-balloon group (n  54). Baseline parameters were
imilar in both groups (Tables 1 and 2). The mean age of
the study population was 66 years at the time of enrollment
in the study. Most patients had multivessel coronary artery
disease. The pattern of ISR was predominantly diffuse. One
patient assigned to the uncoated-balloon group was errone-
ously treated with a DCB catheter taken from a nonassigned
set but was analyzed by intention-to-treat with the
uncoated-balloon group.
Angiographic follow-up at 6 months was available in
49 of 54 patients (91%) in the uncoated-balloon group
and in 47 of 54 patients (87%) in the DCB group. After
6 months, in-segment late lumen loss was reduced from
0.80  0.79 mm with the uncoated balloon to 0.11 
0.44 mm in the paclitaxel-coated balloon group (p 
0.001) (Table 2).
Clinical follow-up was available after 5.4  1.2 years on
average (maximum 6.4 years) (Fig. 1). Eight patients from
the uncoated-balloon group and 5 from the coated-balloon
group died during this period. Furthermore, 8 myocardial
infarctions occurred in the uncoated-balloon group and 5 in
the coated-balloon group. The incidence of major adverse
cardiac events was significantly reduced from 59% in the
uncoated group to 28% in patients treated with the drug-
coated balloon (p  0.002). This difference was mainly
driven by the reduction of target lesion revascularization
from 39% to 9% (Table 3). No stent thrombosis occurred in
both groups. Between 2 and 5 years, 5 target lesion revascu-
larizations occurred. It was the first target lesion revasculariza-
tion for 1 patient in the uncoated-balloon group and 2
patients in the coated-balloon group. Two further patients
had their second target lesion revascularizations (1 patient
from the uncoated-balloon and 1 patient from the coated-
balloon groups). Table 4 summarizes the number of patients
with major adverse cardiovascular events between 2 and 5
years. The Kaplan-Meier curves of major adverse cardiovas-
cular events for the 2 groups over up to 6.4 years are shown
in Figure 2.
Four patients presenting with DES-ISR were included.
In 2 cases, they were randomized to treatment with un-
coated balloons and in 2 cases with DCBs. Both patients
treated with uncoated balloons underwent target lesion
revascularization, whereas no major adverse cardiovascular
events occurred in the 2 patients treated with the DCB.Discussion
Treatment of coronary ISR remains a challenge. Despite
increasing DES use, the expansion of indications for per-
cutaneous coronary intervention to high-risk patients and
complex lesions leads to an increasing total number of
patients suffering from ISR (14). Conventional balloon
angioplasty as treatment modality for BMS-ISR is limited
by high restenosis rates of about 40% to 60% (15,16). Other
approaches, such as the implantation of a second, uncoated
stent or mechanical debulking have not been associated with
a significant reduction in recurrent in-stent restenosis.
Intracoronary radiation (brachytherapy) was the first effec-
tive treatment in this setting, with recurrence rates of 16%
to 23% (17). Meanwhile, the implantation of a DES in a
restenotic BMS has become the most accepted approach.
Repeated restenosis rates after implantation of a DES for
the treatment of BMS-ISR vary between 16% and 21%
(12,15) and are about 20% for the treatment of DES-ISR
independent from the antiproliferative drug used (18).
DCBs offer a new therapeutic option in such high-risk
patients suffering from ISR. The concept of DCB avoids the
implantation of a second layer of metal. Furthermore, a
Table 4. Number of Patients With TLR, MI, Stroke, Death, and
Other Cardiovascular Events Observed Between 2 and 5 Years
Uncoated
Balloon
Drug-Coated
Balloon p Value
MACE
Patients with available data at
5 yrs
37 47
Target lesion revascularization* 2 (3.7) 3 (5.6) 1.00
First TLR 1 2
Second TLR 1 1
Myocardial infarction* 4 (7.4) 4 (7.4) 0.89
NSTEMI non-TV/TV/TL 1/0/2 2/0/0
STEMI non-TV/TV/TL 1/0/0 1/1/0
Death* 5 (9.3) 3 (5.6) 0.43
Cardiac death 2 1
Noncardiac death 1 1
Death of unknown cause 2 1
Stent thrombosis* 0 (0) 0 (0) 1.00
Stroke* 3 (5.6) 3 (5.6) 1.00
MACE* 12 (22.2) 10 (18.6) 0.71
Other cardiovascular events
PCI of a nontarget lesion 10 5
Unscheduled angiography,
unstable angina pectoris,
dyspnea, or chest discomfort
(hospitalization)
20 18
Values are n or n(%). *% refers to total number of included patients.
MACE  major adverse cardiac event(s); MI  myocardial infarction; non-TV  non-target
vessel related; NSTEMI non–ST-segment elevation myocardial infarction; PCI percutaneous
coronary intervention; STEMI  ST-segment elevation myocardial infarction; TL  target lesion
related; TLR target lesion revascularization; TV target vessel related.significant reduction in dual antiplatelet therapy compared
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329with the implantation of a second stent is possible (19). In
the clinical trials with paclitaxel-iopromide–coated balloon
catheters, the duration of dual antiplatelet therapy after
treatment of BMS-ISR varied between 4 weeks (5,11) and
3 months (12). The PEPCAD II ISR study in 131 patients
compared a commercially available DCB (SeQuent Please,
B. Braun, Melsungen, Germany) using the paclitaxel-
iopromide coating with the Taxus stent (Boston Scientific,
Natick, Massachusetts) in the treatment of coronary BMS-
ISR. Compared with the DES, the DCB induced statisti-
cally significantly less in-segment late lumen loss (0.17 
0.42 mm vs. 0.38  0.61 mm; p  0.03), resulting in a
lower binary restenosis rate (7% vs. 20%; p  0.06) at
6-month follow-up (12). In this trial, dual antiplatelet
therapy was extended to 3 months to minimize the effect of
clopidogrel treatment on clinical events. The results of
PEPCAD II compare well with the first-in-human data seen
in this trial with the PACCOCATH prototype balloon (Bayer
AG) (in-segment late lumen loss 0.11  0.44 mm, binary
restenosis rate 6%) (11). Dual antiplatelet therapy was limited
to 4 weeks in both groups. Even during long-term follow-up,
no cases of stent thrombosis occurred.
The results of PACCOCATH ISR (5,11) and PEPCAD
II (12) led to a class IIa recommendation in the European
guidelines for revascularization on the treatment of
BMS-ISR (20). Both trials studied paclitaxel-iopromide–
Figure 2. Event-Free Survival From TLR
Event-free survival from target lesion revascularization (TLR), myocardial infarc
analysis).coated balloon catheters. Therefore, this recommendation islimited to the respective lesion characteristics of the studies and
DCB based on the paclitaxel-iopromide coating (20). So far,
the longest available clinical follow-up was 2 years (11).
Meanwhile, a randomized study in 50 patients with
sirolimus DES-ISR demonstrated a significant reduction of
in-segment late lumen loss with SeQuent Please DCB
compared with conventional angioplasty (0.18  0.45 mm
vs. 0.72  0.55 mm; p  0.001). Furthermore, recurrent
estenosis (8.7% vs. 62.5%; p  0.0001) and survival free of
ajor adverse cardiovascular events were significantly better
n the DCB group (96% vs. 60%; p  0.005) (16).
Concerns have been raised that a short-term local drug
pplication may not result in a long-lasting inhibition of
estenosis. Delayed restenosis of sirolimus- and paclitaxel-
luting stents was found (21–23), but this is not the case
fter BMS implantation (23). In contrast to these findings,
he long-term clinical follow-up of this first-in-human
tudy on the prototype paclitaxel-iopromide–coated balloon
n BMS-ISR revealed no evidence for delayed restenosis or
ther potential local or systemic adverse events. The initial
enefit seen by the reduced target lesion revascularization
ates was maintained during a mean follow-up of more than
years.
Study limitations. The limited number of patients and the
selection of conventional angioplasty as comparison are
I), stroke, and death (n  108). Log-rank (Mantel-Cox, intention-to-treattion (Mlimitations of this study. However, when starting the trial in
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 3 , 2 0 1 2
M A R C H 2 0 1 2 : 3 2 3 – 3 0
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3302003, DES were not accepted as a valuable treatment option
for BMS-ISR.
Conclusions
In a more than 5-year period after treatment of coronary
BMS-ISR with a paclitaxel-iopromide–coated balloon, the
initial results were sustained compared with an identical
uncoated balloon. In contrast to DES, DCB allow a local
intravascular drug delivery without the need for stent
implantation. Furthermore, dual antiplatelet therapy was
given for only 4 weeks.
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